original ) (raw )Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms
B. Gordts
Antimicrobial Agents and Chemotherapy, 1983
View PDFchevron_right
Antibacterial Activity In Vitro and Regression Studies for Ceftazidime and Ceftriaxone
Niels Frimodt-møller
Acta Pathologica Microbiologica Scandinavica Series B: Microbiology, 2009
View PDFchevron_right
Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis
Tobias Welte
Journal of Antimicrobial Chemotherapy, 2003
View PDFchevron_right
A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteremia treated with cefepime or ceftazidime
Chris Gentry
Diagnostic Microbiology and Infectious Disease, 2017
View PDFchevron_right
Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-Abdominal Infections, Complicated Urinary Tract Infections and Nosocomial Pneumonia
Wright W Nichols
Antimicrobial Agents and Chemotherapy
View PDFchevron_right
Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics
Alexander Vinks
Journal of Antimicrobial Chemotherapy, 1997
View PDFchevron_right
Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review
Alex Soriano
Infectious Diseases and Therapy, 2021
View PDFchevron_right
Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia
Wright W Nichols
European Journal of Clinical Pharmacology
View PDFchevron_right
Effect of Treatment Duration on Pharmacokinetic/Pharmacodynamic Indices Correlating with Therapeutic Efficacy of Ceftazidime in Experimental Klebsiella pneumoniae Lung Infection
Wil Goessens
Antimicrobial Agents and Chemotherapy, 2006
View PDFchevron_right
Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model
María-José Giménez
Journal of Antimicrobial Chemotherapy, 2005
View PDFchevron_right
The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study
Claudie Charbonneau
Infectious Diseases and Therapy
View PDFchevron_right
Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa
Roberto Luzzati
International journal of antimicrobial agents, 2016
View PDFchevron_right
In Vitro Activity of Ceftazidime, Cefotaxime and Gentamicin Against 11,521 Clinical Isolates of Bacteria
M. Steinbakk
Acta Pathologica Microbiologica Scandinavica Series B: Microbiology, 2009
View PDFchevron_right
Ceftazidime and amikacin alone and in combination against Pseudomonas aeruginosa and Enterobacteriaceae
Dale Gerding
Diagnostic Microbiology and Infectious Disease, 1987
View PDFchevron_right
Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae
Hjalmar Lagast
Antimicrobial Agents and Chemotherapy, 1983
View PDFchevron_right
A Phase 3 Randomized Double-blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime plus Linezolid for the Treatment of Hospital-acquired Pneumonia
Samir Awad
Clinical Infectious Diseases, 2014
View PDFchevron_right
Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa
Wright W Nichols
Antimicrobial agents and chemotherapy, 2018
View PDFchevron_right
Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: A retrospective, nonrandomized, open-label, historical chart review
Alejandro Jimenez
Clinical Therapeutics, 2007
View PDFchevron_right
Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome
Andy Hoepelman
Antimicrobial Agents and Chemotherapy, 1994
View PDFchevron_right
Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012–2016
Elmano Ramalheira
Diagnostic Microbiology and Infectious Disease, 2019
View PDFchevron_right
Assessment of the Appropriateness of Ceftazidime Use in a Tertiary Teaching Hospital, Northern Ethiopia
Hiluf Hindeya Gebreyesus
Drug, Healthcare and Patient Safety, 2019
View PDFchevron_right
Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales
Roberto Luzzati
Antibiotics, 2020
View PDFchevron_right
Better Outcome of High-Dose Ceftazidime in Hemato – Oncological Patients with Infections Caused by Extensively Drug-Resistant Pseudomonas Aeruginosa
Pavla Paterova
Mediterranean Journal of Hematology and Infectious Diseases
View PDFchevron_right
Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)
Ronald Jones
Journal of Antimicrobial Chemotherapy, 2014
View PDFchevron_right
Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia
David Woodard
Antimicrobial Agents and Chemotherapy, 1985
View PDFchevron_right
Impact of Ceftazidime Use on Susceptibility Patterns in the Neonatal Intensive Care Unit
Robert Welliver
The Pediatric Infectious Disease Journal, 2018
View PDFchevron_right
Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats
Fanak Fahimi
Antimicrobial Agents and Chemotherapy, 1986
View PDFchevron_right
Exposure–Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP
Julie Passarell
Antimicrobial Agents and Chemotherapy
View PDFchevron_right
Monte Carlo Simulations Based on Phase 1 Studies Predict Target Attainment of Ceftobiprole in Nosocomial Pneumonia Patients: a Validation Study
Johan Mouton
Antimicrobial Agents and Chemotherapy, 2013
View PDFchevron_right
Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation
Fritz Soergel
Journal of Antimicrobial Chemotherapy, 2007
View PDFchevron_right